Clinical Trial Update: Intermittent Liposomal Amphotericin B Primary Prophylaxis [Phase 2]

View source ↗

Summary

An update on a Phase 2 trial evaluating intermittent liposomal amphotericin B as primary prophylaxis for fungal infections in Acute Myeloid Leukemia patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AMBISOME (AMPHOTERICIN B)

Snippet

Sponsor: Bayside Health | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: UNKNOWN